Koo - RVXoldtimer, I am not sure that in a ROFR RVX would be in a position to set the price for Apabetalons for the USA the way you suggested.

I would say that in your statement above, you are saying that I inferred that RVX sets the price and you say, "the way you (I) suggested." 

This is not a pre-priced item on a shelf that Pharma picks up and go to a checkout to pay. There is a dialogue and when a Pharma is happy, they will make an offer. RVX will use consultants like Rothschild to decide if it is a fair price or not and if they deem so, they will let HL have first shot at it. I doubt you will find RVX setting a price and going to HL. If HL turned it down, they would not have any alternate offer to go to. I believe they will have an alternate offer first and let HL have first shot. 

I have not counted HL out. My point was that the expiration is getting very close and quite possibly will be reached before top line data is released. I doubt that HL would exercise their option without top line results. That is why I said it would probably expire. The exception as someone posted would be some kind of ROFR renegotiation which might or should include more cash.